Analysts Issue Forecasts for XFOR Q3 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Research analysts at Brookline Cap M issued their Q3 2026 earnings per share (EPS) estimates for X4 Pharmaceuticals in a note issued to investors on Tuesday, March 17th. Brookline Cap M analyst L. Cann expects that the company will earn ($0.27) per share for the quarter. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. Brookline Cap M also issued estimates for X4 Pharmaceuticals’ Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.04) EPS, FY2027 earnings at ($0.96) EPS, FY2028 earnings at ($0.24) EPS and FY2029 earnings at $0.85 EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings results on Tuesday, March 24th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.14. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%. The firm had revenue of $2.57 million for the quarter, compared to the consensus estimate of $1.68 million.

XFOR has been the topic of a number of other research reports. Zacks Research cut shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Stifel Nicolaus set a $10.00 price target on X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen lowered X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th. Finally, Guggenheim initiated coverage on X4 Pharmaceuticals in a research note on Monday, March 9th. They set a “buy” rating and a $12.00 price objective for the company. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $28.88.

X4 Pharmaceuticals Price Performance

NASDAQ:XFOR opened at $4.28 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.48 and a current ratio of 10.16. The company has a 50-day moving average of $3.67 and a 200-day moving average of $3.62. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $9.56. The company has a market capitalization of $389.14 million, a price-to-earnings ratio of -0.99 and a beta of 0.43.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of XFOR. Indivisible Partners bought a new stake in X4 Pharmaceuticals during the 4th quarter worth approximately $40,000. Rhumbline Advisers raised its position in X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares during the last quarter. Two Sigma Investments LP bought a new position in X4 Pharmaceuticals in the 3rd quarter valued at $47,000. Squarepoint Ops LLC acquired a new position in X4 Pharmaceuticals in the fourth quarter worth $50,000. Finally, Stifel Financial Corp acquired a new position in X4 Pharmaceuticals in the fourth quarter worth $82,000. 72.03% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about X4 Pharmaceuticals

Here are the key news stories impacting X4 Pharmaceuticals this week:

• Positive Sentiment: Brookline materially improved its FY2026 EPS view (from -$1.50 to -$1.04), a smaller near‑term loss that suggests a faster path toward profitability. Brookline Cap M FY2026 estimate
• Positive Sentiment: Brookline raised its FY2027 EPS forecast (from -$1.70 to -$0.96), reducing multi‑year downside and improving the medium‑term outlook. Brookline Cap M FY2027 estimate
• Positive Sentiment: Brookline lifted its FY2028 estimate (from -$0.42 to -$0.24), another sign of improving expected margins in later years. Brookline Cap M FY2028 estimate
• Positive Sentiment: Brookline published a long‑range FY2030 EPS projection of $2.85, signaling significant upside potential if X4 hits longer‑term commercialization and scaling assumptions. Brookline Cap M FY2030 estimate
• Neutral Sentiment: Brookline provided updated quarterly EPS forecasts for 2026 (Q1: -$0.20, Q2: -$0.23, Q3: -$0.27, Q4: -$0.34) that set expectations for near‑term performance but are routine analyst guidance updates rather than company‑driven news. Brookline Cap M quarterly estimates
• Negative Sentiment: Brookline cut its FY2029 EPS forecast sharply (from $1.52 to $0.85), lowering medium‑term upside and indicating the analyst reduced confidence in the timing/scale of revenue or margin improvements for that year. Brookline Cap M FY2029 revision

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.